Bronchial mucosal inflammation and illness severity in response to experimental rhinovirus infection in COPD.
B-Lymphocyte Subsets
/ immunology
Biomarkers
Eosinophils
Female
Humans
Inflammation Mediators
Leukocyte Count
Male
Neutrophils
Picornaviridae Infections
/ complications
Pulmonary Disease, Chronic Obstructive
/ complications
Respiratory Function Tests
Respiratory Mucosa
/ pathology
Rhinovirus
Severity of Illness Index
Sputum
/ cytology
T-Lymphocyte Subsets
/ immunology
Rhinovirus infection
chronic obstructive pulmonary disease exacerbation
eosinophils
inflammation
Journal
The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
22
11
2019
revised:
06
03
2020
accepted:
27
03
2020
pubmed:
14
4
2020
medline:
16
3
2021
entrez:
14
4
2020
Statut:
ppublish
Résumé
Respiratory viral infection causes chronic obstructive pulmonary disease (COPD) exacerbations. We previously reported increased bronchial mucosa eosinophil and neutrophil inflammation in patients with COPD experiencing naturally occurring exacerbations. But it is unclear whether virus per se induces bronchial mucosal inflammation, nor whether this relates to exacerbation severity. We sought to determine the extent and nature of bronchial mucosal inflammation following experimental rhinovirus (RV)-16-induced COPD exacerbations and its relationship to disease severity. Bronchial mucosal inflammatory cell phenotypes were determined at preinfection baseline and following experimental RV infection in 17 Global Initiative for Chronic Obstructive Lung Disease stage II subjects with COPD and as controls 20 smokers and 11 nonsmokers with normal lung function. No subject had a history of asthma/allergic rhinitis: all had negative results for aeroallergen skin prick tests. RV infection increased the numbers of bronchial mucosal eosinophils and neutrophils only in COPD and CD8 Experimental RV infection induces bronchial mucosal eosinophilia and neutrophilia only in patients with COPD and monocytes/macrophages and lymphocytes in both patients with COPD and control subjects. The virus-induced inflammatory cell phenotypes observed in COPD positively related to virus load and illness severity. Antiviral/anti-inflammatory therapies could attenuate bronchial inflammation and ameliorate virus-induced COPD exacerbations.
Sections du résumé
BACKGROUND
Respiratory viral infection causes chronic obstructive pulmonary disease (COPD) exacerbations. We previously reported increased bronchial mucosa eosinophil and neutrophil inflammation in patients with COPD experiencing naturally occurring exacerbations. But it is unclear whether virus per se induces bronchial mucosal inflammation, nor whether this relates to exacerbation severity.
OBJECTIVES
We sought to determine the extent and nature of bronchial mucosal inflammation following experimental rhinovirus (RV)-16-induced COPD exacerbations and its relationship to disease severity.
METHODS
Bronchial mucosal inflammatory cell phenotypes were determined at preinfection baseline and following experimental RV infection in 17 Global Initiative for Chronic Obstructive Lung Disease stage II subjects with COPD and as controls 20 smokers and 11 nonsmokers with normal lung function. No subject had a history of asthma/allergic rhinitis: all had negative results for aeroallergen skin prick tests.
RESULTS
RV infection increased the numbers of bronchial mucosal eosinophils and neutrophils only in COPD and CD8
CONCLUSIONS
Experimental RV infection induces bronchial mucosal eosinophilia and neutrophilia only in patients with COPD and monocytes/macrophages and lymphocytes in both patients with COPD and control subjects. The virus-induced inflammatory cell phenotypes observed in COPD positively related to virus load and illness severity. Antiviral/anti-inflammatory therapies could attenuate bronchial inflammation and ameliorate virus-induced COPD exacerbations.
Identifiants
pubmed: 32283204
pii: S0091-6749(20)30427-9
doi: 10.1016/j.jaci.2020.03.021
pmc: PMC7173046
pii:
doi:
Substances chimiques
Biomarkers
0
Inflammation Mediators
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
840-850.e7Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0600879
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 083,567/Z/07/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Lancet. 2007 Sep 1;370(9589):786-96
pubmed: 17765528
Am J Respir Crit Care Med. 2001 Jul 1;164(1):109-16
pubmed: 11435248
Chest. 2016 Jan;149(1):62-73
pubmed: 25790167
Respirology. 2011 Feb;16(2):264-8
pubmed: 21272142
Am J Respir Crit Care Med. 2001 Nov 1;164(9):1618-23
pubmed: 11719299
N Engl J Med. 2013 Jun 27;368(26):2455-66
pubmed: 23688323
Br Med J (Clin Res Ed). 1985 Nov 2;291(6504):1235-9
pubmed: 3933614
Eur Respir J. 2000 Oct;16(4):677-83
pubmed: 11106212
Eur Respir J. 2005 Apr;25(4):640-6
pubmed: 15802337
Respir Med. 1994 Mar;88(3):165-94
pubmed: 8209067
N Engl J Med. 2009 Mar 5;360(10):973-84
pubmed: 19264686
Inflammation. 2013 Oct;36(5):1178-85
pubmed: 23681903
N Engl J Med. 2017 Oct 26;377(17):1613-1629
pubmed: 28893134
Med Sci (Basel). 2018 Sep 11;6(3):
pubmed: 30208605
N Engl J Med. 2019 Sep 12;381(11):1023-1034
pubmed: 31112385
Eur Respir J. 2014 Dec;44(6):1697-700
pubmed: 25323230
Am J Respir Crit Care Med. 2011 Mar 15;183(6):734-42
pubmed: 20889904
Am J Respir Crit Care Med. 2012 Jul 1;186(1):48-55
pubmed: 22447964
Am J Respir Crit Care Med. 2017 May 1;195(9):1189-1197
pubmed: 28278391
Eur Respir J. 2000 Jan;15(1):109-15
pubmed: 10678630
Am J Respir Crit Care Med. 2003 Oct 15;168(8):968-75
pubmed: 12857718
Chest. 2012 Aug;142(2):347-357
pubmed: 22871757
Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):822-6
pubmed: 9517597
Am J Respir Crit Care Med. 2006 May 15;173(10):1114-21
pubmed: 16484677
AMA Arch Intern Med. 1958 Feb;101(2):267-78
pubmed: 13497324
Am J Respir Crit Care Med. 2012 Dec 1;186(11):1117-24
pubmed: 23024024
Clin Infect Dis. 2003 Jun 15;36(12):1523-32
pubmed: 12802751
BMJ Open. 2019 Jan 28;9(1):e024330
pubmed: 30696679
N Engl J Med. 2004 Jun 24;350(26):2645-53
pubmed: 15215480
Antimicrob Agents Chemother. 1999 Sep;43(9):2109-15
pubmed: 10471549
Eur Respir J. 2006 Jan;27(1):60-4
pubmed: 16387936
Eur Respir J. 1996 Nov;9(11):2250-5
pubmed: 8947068
J Clin Microbiol. 1993 Jan;31(1):111-7
pubmed: 8380179
Eur Respir J. 2000 Mar;15(3):512-6
pubmed: 10759445
Am J Respir Crit Care Med. 2011 Sep 15;184(6):662-71
pubmed: 21680942
Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1646-52
pubmed: 7952628
Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22
pubmed: 9603117
Respir Res. 2006 Sep 06;7:116
pubmed: 16956406
J Virol Methods. 1999 Jul;80(2):179-85
pubmed: 10471027
Am J Respir Crit Care Med. 1998 Oct;158(4):1277-85
pubmed: 9769292
Med Sci (Basel). 2018 Jun 08;6(2):
pubmed: 29890705
Am J Respir Crit Care Med. 1997 Mar;155(3):852-7
pubmed: 9117016
J Clin Microbiol. 2004 Mar;42(3):981-6
pubmed: 15004041
Lancet Respir Med. 2019 Aug;7(8):699-709
pubmed: 31122894
N Engl J Med. 2009 Jun 4;360(23):2445-54
pubmed: 19494220
Infection. 2008 Oct;36(5):427-33
pubmed: 18795228
Am J Respir Crit Care Med. 1996 Feb;153(2):629-32
pubmed: 8564109
South Med J. 2009 Mar;102(3):277-82
pubmed: 19204646